Zenas BioPharma (NASDAQ:ZBIO) Stock Rating Reaffirmed as “Buy” by HC Wainwright

Zenas BioPharma (NASDAQ:ZBIO)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report released on Wednesday, Marketbeat reports. They currently have a $44.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 61.88% from the stock’s previous close.

Several other research firms have also issued reports on ZBIO. Guggenheim reiterated a “buy” rating and issued a $55.00 target price on shares of Zenas BioPharma in a research note on Friday, August 14th. Citigroup restated a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Wedbush restated an “outperform” rating and set a $45.00 price target on shares of Zenas BioPharma in a research note on Friday, August 14th. Weiss Ratings lowered Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 9th. Finally, Wall Street Zen raised Zenas BioPharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $45.71.

Zenas BioPharma Price Performance

ZBIO stock traded up $0.42 during midday trading on Wednesday, hitting $27.18. The company’s stock had a trading volume of 290,665 shares, compared to its average volume of 816,773. The company has a quick ratio of 9.93, a current ratio of 9.93 and a debt-to-equity ratio of 1.57. The firm has a market capitalization of $1.77 billion, a price-to-earnings ratio of -3.03 and a beta of -1.04. Zenas BioPharma has a 12 month low of $13.50 and a 12 month high of $44.60. The company has a 50 day moving average of $31.47 and a two-hundred day moving average of $25.08.

Zenas BioPharma (NASDAQ:ZBIO) last posted its earnings results on Wednesday, August 12th. The company reported ($1.77) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.65). The firm had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $15.00 million. On average, analysts expect that Zenas BioPharma will post -5.81 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Quantbot Technologies LP acquired a new position in shares of Zenas BioPharma during the 2nd quarter worth approximately $49,000. ProShare Advisors LLC acquired a new position in shares of Zenas BioPharma during the 4th quarter worth approximately $211,000. Jupiter Topco LLC acquired a new position in shares of Zenas BioPharma during the 2nd quarter worth approximately $201,000. The Manufacturers Life Insurance Company acquired a new position in shares of Zenas BioPharma during the 2nd quarter worth approximately $204,000. Finally, Sei Investments Co. purchased a new stake in shares of Zenas BioPharma during the first quarter worth approximately $242,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for patients with immune-mediated diseases. The company’s research and development efforts are centered on therapies that modulate the immune system and address conditions with significant unmet medical needs.

Zenas’ lead investigational product is obexelimab, an immune-modulating monoclonal antibody designed to inhibit the activity of certain B cells without broadly depleting them. The company is evaluating obexelimab in autoimmune and inflammatory diseases, including IgG4-related disease and systemic lupus erythematosus.